Prof. Taofeek Owonikoko discusses recent changes in the treatment landscape of extensive-stage small cell lung cancer and the challenges associated with identifying therapeutic targets in this disease.1/3 Next Interview
Dr Viola Zhu reviews the evidence behind US Food and Drug Administration (FDA) approvals of targeted treatments for relapsed small cell lung cancer and implications for patient management.2/3 Next Interview
Prof. Giuseppe Giaccone outlines the emerging molecular classification of small cell lung cancer, and potential therapeutic approaches and biomarkers currently being investigated in this disease.3/3 Take CME Test
Overview & Learning Objectives
In this activity, three leading experts discuss the evolving treatment landscape of extensive-stage SCLC and review the latest clinical trial data for emerging therapies in this field.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity has been designed to meet the educational needs of oncology specialists involved in the management of patients with small cell lung cancer.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. Owonikoko discloses (as of September 2020): Research support (to institution) from Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers, Eisai, Fujifilm, G1 Therapeutics, Incyte, Ipsen, Loxo/Lilly, Merck, Mersana, Novartis, Oncorus, Pfizer, Regeneron, Roche/Genentech , StemCentRx, Turning Point and United Therapeutics; Consulting/advisory board fees from Abbvie, Amgen, ARMO BioSciences, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Ipsen, Jazz, Lilly, MedImmune, Merck, Novartis, PharmaMar, Sandoz, XCovery and Zentalis; Independent review committee/data safety monitoring board fees from EMD Serono and Roche/Genentech; Stockholdings /co-founder of Cambium Oncology.
Dr Viola Zhu discloses: Consultancy/advisory board fees from AstraZeneca, Roche/Genentech, Takeda, Xcovery; Stockholdings in TP Therapeutics (until May 2020); Speakers bureau fees from AstraZeneca, Blueprint, Roche/Genentech and Takeda.
Prof. Giuseppe Giaccone has no financial interests/relationships of affiliations to disclose in relation to this activity.
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Hennah Patel, MPharm, RPh, has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 25 March 2021. Date credits expire: 25 March 2022.
After watching this activity, participants should be better able to:
- Summarize the current treatment recommendations for SCLC and how they are evolving as new agents emerge
- Evaluate the efficacy and safety of emerging agents for relapsed SCLC
- Describe emerging treatment options and ongoing clinical trials for relapsed SCLC